drugset / Trial / NCT03231228
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a Phase 4, open-label, single-dose, parallel-group, multicenter, safety study of cefazolin (1 g or 2 g) in pediatric subjects between 10 and 17 years of age (inclusive) scheduled for surgery.
Timeline
- Start
- 2017-11-20
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cefazolin | Small molecule | 1 g | Intravenous |
| Comparator | Cefazolin | Small molecule | 2 g | Intravenous |
Indications
No indication recorded.